Alnylam Pharmaceuticals | ALNY - Current Assets

Stock Price
315.71
Daily Change
2.30 0.73%
Monthly
-5.08%
Yearly
24.73%
Q1 Forecast
303.95

Alnylam Pharmaceuticals reported $4.05B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Moderna USD 6.54B 54M Dec/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 28.2B 2.26B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Takeda JPY 3.12T 195.82B Dec/2025
Tectonic Therapeutic USD 273.24M 17.61M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025
Xencor USD 599.82M 81.38M Dec/2025